Propanc Biopharma plans to acquire a digital asset finance firm with a market capitalization below net asset value

On November 4th, according to Globenewswire, digital asset finance company Propanc Biopharma (NASDAQ: PPCB) announced a strategic plan to acquire digital asset management (DAT) companies that currently have a market capitalization-to-net asset value (MNAV) ratio below their trading. Company management believes that the acquisition of undervalued digital asset technology (DAT) companies is a great opportunity to strengthen Propanc's balance sheet, diversify its assets, and create long-term shareholder value. These DAT companies typically hold large amounts of mainstream digital assets such as Bitcoin and Ethereum on their balance sheets. Propanc's board and executive team are currently evaluating potential acquisition targets and developing a due diligence framework to assess balance sheet strength, digital asset holdings, and operational synergy effects.